"He went through six operations and was placed on a clinical trial so he could try new treatments.”
A trial looking at imatinib for glioma brain tumours (EORTC 16011-26013)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
The aims of this trial were to find out
- How well imatinib works for people with glioma
- More about the side effects
Summary of results
The researchers in this trial found that imatinib did not help people with glioma brain tumours that had come back.
Everybody who took part had imatinib. Some people had a higher dose of imatinib than others. This depended on how the treatment was working. On average, people had 2 cycles of treatment.
The trial team analysed the results in 2008. They found
- In 5 people the cancer slowed or stopped growing – doctors call this a
- In 27 people the cancer stayed the same – doctors call this
- The treatment did not work for anybody else who took part
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Martin van den Bent
European Organisation for Research and Treatment of Cancer (EORTC)